PRFX PainReform Ltd.

We are a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics.

As of 10/18/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  Israel
Country of incorporation:  
IPO date:  09/01/2020
Outstanding shares:  10,482,056
Average volume:  125,079
Market cap:   $28,301,551
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.46
PS ratio:   0.00
Return on equity:   -31.67%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy